Quelles nouveautes en 2008 dans le cancer du rein ?

25 mai 2009

Auteurs : V. Phé, M. Rouprêt, E. Lechevallier, J.-J. Patard
Référence : Prog Urol, 2009, 19, S56, suppl. S2

Les travaux les plus innovants présentés lors des congrès internationaux 2008 dans le domaine du cancer du rein ont été sélectionnés. Pour le cancer du rein localisé, l’une des innovations diagnostiques est représentée par l’échographie de contraste. De nombreuses communications ont porté sur les marges positives chirurgicales et leur impact ainsi que les éléments conduisant à une altération de la fonction rénale après néphrectomie. La néphrectomie laparoscopique assistée par robot semble être une technique sûre et efficace. Les traitements mini-invasifs peuvent être intéressants. Pour le cancer du rein métastatique, le sunitinib a été comparé à l’IFN-⍺ en première ligne et des données de survie sont disponibles. L’everolimus pourrait devenir un traitement de seconde ligne de référence après echec d’inhibiteur de tyrosine kinase.




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Mejean A., Correas J.M., Escudier B., de Fromot M., Lang H., Long J.A., et al. Tumeurs du rein Prog Urol 2007 ;  17 : 1101-1144 [cross-ref]
Pallwein L., Mitterberger M., Gradl H., Aigner F., Pinggera G., Strasser H. Diagnostic evaluation of small renal masses: value of contrast-enhanced US in comparison to multidectector CT J Urol 2008 ;  179 (Suppl) : 4(abstract no 960).
Pallwein L., Mitterberger M., Gradl J., Aigner F., Strasser H., Peschel R., et al. Value contrast-enhanced ultrasound in the diagnostic evaluation of complex cystic renal lesions J Urol 2008 ;  179 (Suppl) : 4(abstract no 1208).
Mattar K., Basiuk J., Finelli A., Fleshner N., Pautler S., Chin J., et al. Active surveillance of small renal masses: A prospective multicentre Canadian trial Eur Urol Suppl 2008 ;  7 : 3(abstract no 951).
Kaplan D.J., Kunkle D.A., Saad I.R., Egleston B.L., Uzzo R.G. Kidney cancer anc dompeting causes of mortality: an age-based population study J Urol 2008 ;  179 (Suppl) : 4(abstract no 478).
Uzzo R.G., Egleston B.L., Wong Y. A comprehensive nomogram evaluating competing risks of death in patients with localized renal cell carcinoma J Urol 2008 ;  179 (Suppl) : 4(abstract no 961).
Koenig F.P., Gill I.S., Kamoi K., Aron M., Haber G.P., Singh A.B., et al. Kidney cancer and the risk for chronic kidney disease: matched-paired comparising with living donors J Urol 2008 ;  179 (Suppl) : 4(abstract no 484).
Lucas S.M., Ylitalo A., Nuss G.R., Adibi M., Raman J., Cadeddu J.A. The scored value predicts patients with small unilateral renal masses at risk for having or developing chronic kidney disease J Urol 2008 ;  179 (Suppl) : 4(abstract no1396).
 [cross-ref]
Stec A.A., Coons B.J., Lowrance W., Chang S.S., Cookson M.S., Herrell S.D., et al. Waiting time from diagnosis to nephrectomy for renal cell carcinoma: does it affect survival? J Urol 2008 ;  179 (Suppl) : 4(abstract no1210).
Jang T.L., Pettus J.A., Huang W.C., Eggener S.E., O'Brien M.F., Karellas M.E., et al. Survival rates after resection for localized kidney cancer: 1989-2004 J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5115).
Bernhard J.C., Ferriere J.M., Pantuck A.J., Robert G., Crepel M., Wallerand H., et al. Predictive factors for local recurrence after nephron sparing surgery in renal cell carcinoma Eur Urol Suppl 2008 ;  7 : 3(abstract no 840).
Patard J.J., Pantuck A.J., Karakiewicz P.I., Mottet N., Zin L., Salomon L., et al. Positive surgical margins appear to have negligible impact on the survival of renal cell carcinomas treated by nephron sparing surgery J Urol 2008 ;  179 (Suppl) : 4(abstract no 1213).
Thompson R.H., Yossepowitch O., Leibovich B.C., Eggener S.E., Pettus J.A., Kwon E.D., et al. Oncologic outcomes for patients with positive surgical margins at partial nephrectomy J Urol 2008 ;  179 (Suppl) : 4(abstract no 1398).
Patard J.J., Bensalah K.C., Pantuck A.J., Montorsi F., Karakiewicz P.I., Mottet N., et al. Are there determinant predictive factors for optimising the management of patients with positive margins following nephron-sparing surgery? Eur Urol Suppl 2008 ;  7 : 3(abstract no 839).
Funahashi Y., Hattori R., Kamihira O., Yamamoto T., Gotoh M. Ischemic damage of nephron-sparing surgery on renal function J Urol 2008 ;  179 (Suppl) : 4(abstract no 950).
Godoy G., Ramanathan V., Kanofsky J., O'Malley R., Tareen B., Taneja S.S., et al. Warm ischemia time during laparoscopic partial nephrectomy: effect on early post-operative glomerular filtration rate J Urol 2008 ;  179 (Suppl) : 4(abstract no 1391).
Kamoi K., Aron M., Turna B., Haber G.P., Berger A., Crouzet S., et al. Factors affecting renal function after laparoscopic partial nephrectomy J Urol 2008 ;  179 (Suppl) : 4(abstract no 1390).
Michli E., Parra R.O. Robotic assisted laparoscopic partial nephrectomy for incidental renal masses: comparison to open partial nephrectomy J Urol 2008 ;  179 (Suppl) : 4(abstract no 607).
Rogers C.G., Metwalli A., Blatt A., Bratslavsky G., Linehan W.M., Pinto P.A. Robotic partial nephrectomy for renal hilar tumors J Urol 2008 ;  179 (Suppl) : 4(abstract no 614).
Porter J.R. Robotic assisted laparoscopic partial nephrectomy J Urol 2008 ;  179 (Suppl) : 4(abstract no 1097).
Williams K., Wingo S., Carey I., Leveillee J. Radiofrequency ablation for renal tumours: Intermediate term results Eur Urol Suppl 2008 ;  7 : 3(abstract no 953).
 [cross-ref]
Stern J., Raman J.D., Cadeddu J. Absence of viable carcinoma in biopsies performed greater than 1-year following radiofrequency ablation of renal cortical tumors J Urol 2008 ;  179 (Suppl) : 4(abstract no 1203).
Langenkamp S., Abusalim N., Huenerbein R., Kuhn F.P., Albers P. Percutaneous radiofrequency ablation (RFA) of renal tumours-embolisation before RFA? Eur Urol Suppl 2008 ;  7 : 3(abstract no 954).
Klingler H., Susani H., Marberger J. Laparoscopic high-intensity focused ultrasound for energy ablative therapy of small renal tumours Eur Urol Suppl 2008 ;  7 : 3(abstract no 487).
Keeley F.X., Laguna M.P., De La Rosette J., Fenn N.J., Anderson C.J., Klingler H.C., et al. Safety and short-term efficacy of laparoscopic cryoablation for renal tumours >3cm: A multicentre European report Eur Urol Suppl 2008 ;  7 : 3(abstract no 486).
Aron M., Kamoi K., Haber G.P., Desai M.M., Canes D., Kaouk J.H. Laparoscopic renal cryoablation: long-term oncologic outcomes with minimum 5-year follow-up J Urol 2008 ;  179 (Suppl) : 4(abstract no 596).
Staehler M., Kruse J., Haseke N., Stadler T., Karl A., Bruns C., et al. Effect of metastasectomy on survival in patients with metastatic renal cell cancer: 10 years experience in 240 patients J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5107).
Figlin R.A., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Négrier S. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) J Clin Oncol 2008 ;  26 (Suppl) : (abstract 5024).
Oudard S., Motzer R.J., Michaelson M.D., Hutson T.E., Tomczak P., Bukowski R.M., et al. Sunitinib as first-line treatment for metastatic renal cell carcinoma: Updated results and analysis of prognostic factors from a phase III randomised trial Eur Urol Suppl 2008 ;  7 : 3(abstract no 698).
Lassau N., Koscielny S., Chami L., Benatsou B., Albiges L., Roche A., et al. Dynamic contrast-enhanced ultrasonography with quantification for the early evaluation of metastatic renal cancer treated with tyrosine kinase inhibitors (TKI) J Clin Oncol 2008 ;  26 (suppl) : (abstract no 5049).
Wolter P., Stefan C., Decallonne B., Dumez H., Fieuws S., Wildiers H., et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5126).
Porta C., Szczylik C., Bracarda S., Hawkins R., Bjarnason G.A., Oudard S., et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC) J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5114).
Szczylik C., Porta C., Bracarda S., Hawkins R., Bjarnason G.A., Oudard S., et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC) J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5124).
Margulis V., Matin S.F., Tamboli P., Swanson D.A., Wood C.G. Surgical morbidity associated with administration of targeted molecular therapies prior to cytoreductive nephrectomy for metastatic renal cell carcinoma J Urol 2008 ;  179 (Suppl) : 4(abstract no 604).
Thibault F., Billemont B., Rixe O. Perioperative use and surgical complications of sunitinib in metastatic renal cell carcinoma Eur Urol Suppl 2008 ;  7 : 3(abstract no 941).
Escudier B.J., Ravaud A., Négrier S., Szczylik C., Bellmunt Molins J., Bracarda S., et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5025).
Logan T., McDermott D.F., Dutcher J.P., Makhson A., Mikulas J., Berkenblit A., et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5050).
Motzer R.J., Escudier B., Oudard S., Porta C., Hutson T.E., Bracarda S., et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase- III study J Clin Oncol 2008 ;  26 (Suppl) : (abstract no LBA5026).
Jac J., Amato R.J., Giessinger S., Saxena S., Willis J.P. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5113).
Shepard D.R., Rini B.I., Garcia J.A., Hutson T.E., Elson P., Gilligan T., et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5123).
Amato R.J., Jac J., Harris P., Dalton M., Saxena S., Monzon F., et al. A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC) J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5122).
Bukowski R.M., Stadler W.M., Figlin R.A., Knox J.J., Gabrail N., McDermott D.F., et al. Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America J Clin Oncol 2008 ;  26 (Suppl) : (abstract no 5045).






© 2009 
Elsevier Masson SAS. Tous droits réservés.